SNB-101: Orphan Drug Status for Small Cell Lung Cancer in EU


SN Bioscience Co., Ltd., a leading biopharmaceutical company, has recently announced that the European Medicines Agency (EMA) has granted an orphan drug designation for their innovative nano anti-cancer drug, SNB-101, for the treatment of small cell lung cancer (SCLC). This designation comes shortly after the U.S. Food and Drug Administration (FDA) granted SNB-101 a similar status.

SNB-101 is a groundbreaking polymer nanoparticle drug that has shown promise in targeting and treating SCLC, a rare and aggressive form of lung cancer. The orphan drug designation by both the FDA and EMA highlights the potential of SNB-101 to address the unmet medical needs of patients suffering from this devastating disease.

The orphan drug status provides SN Bioscience with various incentives, including market exclusivity and reduced regulatory fees, to support the development and commercialization of SNB-101. The company remains committed to advancing its research and bringing this innovative treatment to patients in need.